Camuzard Olivier, Nollet Marie, Santucci-Darmanin Sabine, Trojani Marie-Charlotte, Ben Abderrahman Nadia, Virolle Virginie, Burel-Vandenbos Fanny, Pagnotta Sophie, Orange François, Kolano-Merlin Ewa, Carle Georges F, Pierrefite-Carle Valérie
UMR E-4320 TIRO-MATOs CEA/DRF/Institut Joliot, Université Côte d'Azur, Faculté de Médecine Nice, France.
Service de Chirurgie Réparatrice et de la Main, CHU de Nice, Nice, France.
Autophagy Rep. 2022 Sep 24;1(1):418-437. doi: 10.1080/27694127.2022.2112125. eCollection 2022.
Osteosarcoma (OS) is a bone cancer exhibiting a 20% survival rate for metastatic patients, which motivates the development of new therapeutic options. Among the various new treatment approaches, modulation of autophagy is the subject of rising interest. In addition to its pro-survival role in established tumors, autophagy recently emerged as an active player in the crosstalk between tumor and stromal cells. In OS, although the knockdown of key autophagy genes in human cell lines demonstrates a protumoral role of autophagy, the analysis of patient tumors indicates that lack of LC3-positive punctae at resection following neoadjuvant chemotherapy is a poor prognostic marker, suggesting that loss of autophagy is not detrimental for the tumor. In the present work, we analyzed the consequences of autophagy inactivation in OS cells both on tumor development and on bone microenvironment in an orthotopic syngeneic model. We found that inactivation of the autophagy-essential gene in OS cells decreases their tumorigenic properties . However, these effects were no longer observed , likely due to microenvironment modifications such as overexpression of the major OS-promoting factor TGF-β or increased infiltration of Foxp3-positive and CD31-positive cells in KO tumors. In addition, autophagy-deficient tumor cells stimulate the formation of osteoclast, the cells in charge of bone resorption which can release bone matrix-embedded growth factors thereby stimulating tumor growth. Taken together, these results suggest that inactivation in OS cells is associated with microenvironment modifications known as poor prognosis-associated factors in OS, and could thus balance the negative cell-autonomous effects of autophagy suppression. : ACTB -β-actin; Atg -autophagy-related; Baf-A1 - Bafilomycin-A1; CSC -cancer stem cells; Col1A -type 1a collagen; d -day; HBSS -Hank's balanced salt solution; LC3 -microtubule-associated protein 1 light chain 3 protein; SQSTM1/p62 -sequestosome; OB -osteoblast; OC -osteoclast; OS -osteosarcoma; TEM -transmission electron microscopy; TGF-β -transforming growth factor β; TRAP -acid phosphatase 5, tartrate-resistant.
骨肉瘤(OS)是一种骨癌,转移性患者的生存率为20%,这推动了新治疗方案的开发。在各种新的治疗方法中,自噬调节是一个越来越受关注的主题。除了其在已建立肿瘤中的促生存作用外,自噬最近还成为肿瘤与基质细胞间相互作用中的一个活跃参与者。在骨肉瘤中,虽然在人细胞系中敲低关键自噬基因显示出自噬的促肿瘤作用,但对患者肿瘤的分析表明,新辅助化疗后切除时缺乏LC3阳性斑点是一个不良预后标志物,这表明自噬缺失对肿瘤并无损害。在本研究中,我们在原位同基因模型中分析了骨肉瘤细胞中自噬失活对肿瘤发展和骨微环境的影响。我们发现,骨肉瘤细胞中自噬必需基因的失活降低了它们的致瘤特性。然而,这些效应不再被观察到,可能是由于微环境的改变,如主要的骨肉瘤促进因子TGF-β的过表达,或在自噬基因敲除肿瘤中Foxp3阳性和CD31阳性细胞浸润增加。此外,自噬缺陷的肿瘤细胞刺激破骨细胞的形成,破骨细胞负责骨吸收,可释放骨基质中嵌入的生长因子,从而刺激肿瘤生长。综上所述,这些结果表明,骨肉瘤细胞中的自噬失活与骨肉瘤中已知的不良预后相关因素的微环境改变有关,因此可以平衡自噬抑制的负细胞自主效应。:ACTB -β-肌动蛋白;Atg -自噬相关;Baf-A1 -巴弗洛霉素-A1;CSC -癌症干细胞;Col1A -1a型胶原蛋白;d -天;HBSS -汉克平衡盐溶液;LC3 -微管相关蛋白1轻链3蛋白;SQSTM1/p62 -聚集体;OB -成骨细胞;OC -破骨细胞;OS -骨肉瘤;TEM -透射电子显微镜;TGF-β -转化生长因子β;TRAP -抗酒石酸酸性磷酸酶5